Diabetes Drugs: Bittersweet Truth of Patent Expiries

The Morning Brief · Jul 25, 2022 · 28m

With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with Nithya Balasubramanian, Director at AB Bernstein, Sheetal Sapale, Marketing President - AWACS, and Vikas Dandekar, Editor - Pharma at ET Prime.

Credits: CNBC-TV18

See omnystudio.com/listener for privacy information.